返回 
加入收藏
冻干重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 冻干重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察冻干重组人脑利钠肽联合左西孟旦治疗急性心力衰竭的临床疗效与安全性，考察该联合用药对患者血清尿酸（UA）与脑钠肽（BNP）水平的影响。方法：68例急性心力衰竭患者依据抽签法随机分为观察组与对照组，各34例。两组患者均给予常规治疗，在此基础上对照组患者给予左西孟旦注射液5 ml加入0.9％氯化钠注射液45 ml中持续微泵注射：开始后第1 h内泵注速率为12 μg/（kg·min），之后以0.5 μg/（kg·min）的速率持续给药23 h；观察组患者在对照组基础上给予冻干重组人脑利钠肽1.5 μg/kg静脉冲击，之后以7.5 ng/（kg·min）的速率持续静脉滴注3～7 d。观察两组患者的临床疗效，治疗前后血清UA、BNP与心功能指标的变化，以及用药安全性。结果：治疗后，观察组患者的总有效率（94.11％）显著高于对照组（70.59％），差异有统计学意义（P＜0.05）；观察组患者的血清UA与BNP水平改善程度明显优于对照组，差异有统计学意义（P＜0.05）；观察组患者的每搏输出量与左心室射血分数明显优于对照组，差异有统计学意义（P＜0.05）。观察组患者的不良反应发生率（2.94％）与对照组（5.88％）比较，差异无统计学意义（P＞0.05）。结论：冻干重组人脑利钠肽联合左西孟旦治疗急性心力衰竭临床疗效明显、安全性高。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of rhBNP combined with levosimendan in the treatment of acute heart failure， and to investigated the effects of drug combination on serum UA and BNP levels. METHODS： 68 patients with acute heart failure were randomly divided into observation group and control group， with 34 cases in each group. Both groups received routine treatment； control group was additionally given Levosimendan injection 5 ml added into 0.9％ Sodium chloride injection 45 ml with persistent micropump injection： at pump rate of 12 μg/（kg·min） within first 1 h， and then at pump rate of 0.5 μg/（kg·min） for consecutive 23 h； observation group was additionally given rhBNP 1.5 μg/kg for intravenous shock， and then given consecutive intravenous injection of rhBNP at rate of 7.5 ng/（kg·min） continuous 3-7 days on the basis of control group. Clinical efficacy of 2 groups were observed， and serum levels of UA and BNP， heart function index， the safety of drug use were observed before and after treatment. RESULTS： After treatment， total effective rate of observation group （94.11％） was significantly higher than that of control group （70.59％）， with statistical significance （P＜0.05）. The improvement of serum levels of UA and BNP in observation group was more significant than in control group， with statistical significance （P＜0.05）. The stroke volume and left ventricular ejection fraction of observation group were significantly better than those of control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between observation group （2.94％） and control group （5.88％） （P＞0.05）. CONCLUSIONS： rhBNP combined with levosimendan have significant clinical efficacy and high safety in the treatment of acute heart failure. |
| 期刊： | 2016年第27卷第8期 |
| 作者： | 曹俊雄，朱志军，吴丹宁 |
| AUTHORS： | CAO Junxiong，ZHU Zhijun，WU Danning |
| 关键字： | 冻干重组人脑利钠肽；左西孟旦；联合用药；急性心力衰竭；尿酸；脑钠肽 |
| KEYWORDS： | rhBNP； Levosimendan； Drug combiration； Acute heart failure； UA； BNP |
| 阅读数： | 367 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
